Dr. Hsu joined Oncternal as Chief Medical Officer in August 2019.He is a medical oncologist with more than 25 years of clinical cancer research and development experience in the biotech industry and academics.Most recently, he served as Vice President and Head of Oncology at Immune Design Corporation prior to its acquisition by Merck Co., Inc., where he was responsible for development of several immuno-oncology programs and first-in-human studies and later stage studies in both hematologic malignancies and solid cancers. Prior to Immune Design, Dr. Hsu served as Chief Medical Officer at Zyngenia, Inc., where he was responsible for development of its multivalent antibody/protein therapeutics. Dr. Hsu started his biotech industry career as a Senior Medical Director at Genzyme Corporation prior to its acquisition by Sanofi, S.A, and over a 10 year period led several multifunctional teams and oversaw the clinical development of multiple investigational and approved agents, including Mozobil®, Campath®, fresolimumab, and other immuno-oncology agents.

Before joining the biotech industry, Dr. Hsu had a distinguished career in academics.He was a faculty member at Yale University, serving as an Assistant Professor of Medicine in the Section of Oncology and co-Director/Director of the Immunology Research Program of the Yale Cancer Center and was a clinical and research fellow with Dr. Ron Levy at Stanford.Dr. Hsu’s basic and translational research was in the development of lymphoma vaccines and antibody therapeutics and included the first clinical trial of a dendritic cell-based vaccine. These clinical studies provided the rationale and basis for the development of Provenge®.Dr. Hsu holds a B.S. degree in biology from Stanford University, and an M.D. degree from Harvard Medical School and the Health Science and Technology Program at the Massachusetts Institute of Technology. He completed his internship/residency in Internal Medicine at the University of California, San Francisco and his oncology training at Stanford University.